Pharmacy Times

JUNE 18, 2025

Martino, PharmD, BCOP, APh Kaitlyn Wells, PharmD Sam Martinez, PharmD, BCOP, BCPS Craig A. Martino, PharmD, BCOP, APh Kaitlyn Wells, PharmD Sam Martinez, PharmD, BCOP, BCPS Craig A.

Immunization 65

Immunization Compounding Pharmacies Hospitals Chemotherapy 65

Pharmacy Times

JUNE 11, 2025

Approximately 40% to 80% of patients with cancer who are assigned female at birth face possible infertility as a result of their cancer treatments, such as chemotherapy, radiation, and surgery. An additional 15% to 30% of cancer survivors who are assigned male at birth also face infertility as a result of chemotherapy.

Specialty Pharmacies 73

Specialty Pharmacies Compounding Pharmacies Immunization Chemotherapy 73

Pharmacy Times

JUNE 17, 2025

Results American Oncology Network (AON) Pharmacy collected data on waste and cost avoidance from February 2023 to September 2023. If a discrepancy is found, the pharmacy nurses will hold the shipment, and a clinical intervention will be communicated to the provider. During this time frame, the pharmacy documented 152 interventions.

Mail-Order Pharmacies 73

Mail-Order Pharmacies Compounding Pharmacies Medical Records Dosage 73

Pharmacy Times

JUNE 23, 2025

From 2003 to 2023, 943 drugs were approved through the 505(b)(2) pathway. As of January 1, 2023, CMS has begun issuing unique J-codes to 505(b)(2) drugs dating back to 2003. “In However, 505(b)(2) drugs have been available since the 1980s.

FDA 65

FDA Compounding Pharmacies Dosage Hospitals 65

Pharmacy Times

JUNE 12, 2025

Clinical Applications and Economic Impacts Biologics have significantly impacted cancer therapies by targeting cancer cells more specifically and reducing adverse events compared with traditional chemotherapy, Darkow noted. billion worth in savings in 2023 and $36 billion since the first biosimilar entered the market in 2015.

Immunization 73

Immunization Compounding Pharmacies FDA Hospitals 73

Pharmacy Times

JUNE 20, 2025

Blood cancer patients are usually at higher risk due to prior chemotherapy, and maybe we don’t need the same kind of prophylactic medications for solid tumor patients. I think we’re getting to the point now where hematology and oncology both need services that can manage these types of side effects. The infection risks are a little different.

Compounding Pharmacies 65

Compounding Pharmacies Immunization Mayo Clinic Hospitals 65

Pharmacy Times

JULY 22, 2025

A man aged 55 years with metastatic colorectal cancer was initiated on a standard fluoropyrimidine-based chemotherapy regimen. Within a week, he developed severe neutropenia, gastrointestinal shutdown, and septic complications requiring admission to the intensive care unit.

Compounding Pharmacies 50

Compounding Pharmacies FDA Hospitals Immunization 50

Pharmacy Times

JUNE 16, 2025

Transportation barriers, as a health-related social need, significantly impact FN rates in chemotherapy patients. Febrile neutropenia (FN) remains a serious and common complication of chemotherapy. A 67% FN rate difference between pegfilgrastim and filgrastim was observed in patients with transportation barriers.

HIV Treatment and Prevention Agents 73

HIV Treatment and Prevention Agents Chemotherapy Compounding Pharmacies Immunization 73

Pharmacy Times

JULY 9, 2025

Although improved clinical outcomes with the addition of chemotherapy to ICI have been recorded for some patients, there is ongoing research to understand how prognostic factors (eg, smoking history, tumor histology, performance status) can provide some predictive values for patient response to ICI therapy. months) and 6.4 months).

Immunization 86

Immunization Compounding Pharmacies FDA Chemotherapy 86

Pharmacy Times

JUNE 13, 2025

Vitamin D supplementation increased 25-hydroxyvitamin-D levels significantly, suggesting a potential role in enhancing chemotherapy effectiveness. The study's findings support further research with larger samples to explore vitamin D's impact on chemotherapy and breast cancer remission likelihood.

Chemotherapy 141

Chemotherapy Immunization Compounding Pharmacies Hospitals 141

Pharmacy Times

JUNE 17, 2025

Eligible patients include adults (≥ 18 years) diagnosed with CML receiving imatinib as first-line therapy for more than 1 month between 2008 and 2023. Materials and Methods This retrospective observational study utilized the Carolina Data Warehouse for Health electronic health record (EHR) database.

Dosage 65

Dosage Compounding Pharmacies Immunization Chemotherapy 65

Pharmacy Times

JUNE 10, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

FDA 73

FDA HIV Treatment and Prevention Agents Compounding Pharmacies Hospitals 73

Pharmacy Times

JUNE 9, 2025

Related Videos Related Content Advertisement June 9th 2025 Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2. Subscribe Now!

Compounding Pharmacies 73

Compounding Pharmacies Hospitals Immunization Chemotherapy 73

Pharmacy Times

JUNE 19, 2025

6 Chimeric antigen receptor (CAR) cell therapies ranked 10th with 795 candidates, holding steady from 2023. The approval of the first CRISPR-Cas9-based therapy in 2023 has accelerated efforts toward allogeneic, off-the-shelf CAR T products. 6 CAR T-cell therapies continue to dominate the genetically modified space. 2024;45(5):406-418.

Compounding 65

Compounding Compounding Pharmacies FDA Immunization 65

Pharmacy Times

JUNE 20, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Compounding 115

Compounding Compounding Pharmacies Patient Care Immunization 115

Pharmacy Times

JULY 23, 2025

So I think the study really showed the benefit of remote clinical monitoring after starting chemotherapy. It frees up appointment slots for patients who need urgent care and helps streamline the process for new patients. Przespolewski : Pharmacists play a large role in managing drug shortages, especially those on the front lines.

Specialty Pharmacies 65

Specialty Pharmacies Hospitals Compounding Pharmacies Immunization 65

Pharmacy Times

JUNE 25, 2025

Yes, we currently have antibody-drug conjugates that are conjugated to a cytotoxic chemotherapy. So are there oncogenic proteins that we can actually target that we couldn’t traditionally target with just a small molecule inhibitor? We look at ADCs. Unfortunately, these drugs are quite toxic.

Compounding Pharmacies 65

Compounding Pharmacies Immunization Hospitals Compounding 65

Pharmacy Times

JUNE 27, 2025

Around late 2023, a friend was diagnosed with metastatic colorectal cancer at 46 years old. After learning of his diagnosis, our relationship shifted from small talk at school events to detailed discussions in an infusion center setting about chemotherapy, immunotherapy, clinical trials, alternative medicines, and anticipated adverse effects.

Compounding Pharmacies 50

Compounding Pharmacies Immunization Chemotherapy Hospitals 50

Pharmaceutical Technology

JULY 4, 2025

Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Reports Future of Pharma - Looking Ahead to 2023 Data Insights The gold standard of business intelligence. Reports Future of Pharma - Looking Ahead to 2023 Data Insights The gold standard of business intelligence.

Chemotherapy 52

Chemotherapy Packaging Communication Hospitals 52

Pharmacy Times

JUNE 9, 2025

Updated March 20, 2023. Related Videos Related Content Advertisement June 9th 2025 Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2. But doing so requires a new kind of expertise that spans science, strategy, and systems thinking.

Compounding Pharmacies 56

Compounding Pharmacies FDA Hospitals Immunization 56

Pharmacy Times

JUNE 11, 2025

Additionally, patients may have received prior chemotherapy for advanced disease. Updated October 30, 2023. Additionally, taletrectinib was granted priority review, breakthrough designation, and orphan drug designation for this indication. Accessed June 11, 2025. ClinicalTrials.gov identifier: NCT04395677. Accessed June 11, 2025.

FDA 73

FDA Compounding Pharmacies Immunization Hospitals 73

Pharmaceutical Technology

JULY 1, 2025

Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Notably, priorities have shifted since 2023 in favour of greater competitiveness, he adds. Reports Biosimilars in Immunology Data Insights The gold standard of business intelligence. Sign up for our daily news round-up!

Packaging 52

Packaging Chemotherapy Communication Hospitals 52

Pharmacy Times

JUNE 18, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Compounding Pharmacies 73

Compounding Pharmacies Dosage Immunization Compounding 73

Pharmacy Times

JULY 14, 2025

TRE-515 Combined With a Radiopharmaceutical As a precision cancer treatment designed for adults with PSMA-positive mCRPC, lutetium Lu 177 vipivotide tetraxetan is used after individuals have undergone other treatments like androgen receptor pathway inhibition and taxane-based chemotherapy.

FDA 73

FDA Compounding Pharmacies Compounding Immunization 73

Pharmacy Times

JUNE 25, 2025

Benmelstobart (TQB2450; Chia Tai Tianqing Pharmaceutical Group Co, Ltd) in combination with chemotherapy followed by sequential combination with anlotinib (Catequentinib; Advenchen Laboratories) led to significant improvements in progression-free survival (PFS), with a manageable safety profile. months versus 7.79 months with tislelizumab.

Chemotherapy 50

Chemotherapy Compounding Pharmacies Immunization Compounding 50

Pharmacy Times

JUNE 18, 2025

Mok : Right now, we have a lot of chemotherapy being used, but there are many more novel treatments being studied, especially in earlier lines of treatment. Bispecifics are moving up in the lymphoma space, and these newer therapies may have some synergistic effects with chemotherapy. REFERENCES 1. Updated August 18, 2021.

Chemotherapy 65

Chemotherapy Compounding Pharmacies Immunization Hospitals 65

Pharmacy Times

JULY 3, 2025

I think it’ll be chemotherapy—maybe their cells being given outpatient—and then, as we hit their hardest time or their highest risk for either febrile neutropenia or mucositis or even some of the toxicities from the chemotherapy, we have them inpatient until we feel comfortable, and then transition it so that it could be all outpatient.

Specialty Pharmacies 65

Specialty Pharmacies Compounding Pharmacies Hospitals Immunization 65

Pharmacy Times

JUNE 19, 2025

1 Biomarker testing is relatively new in the treatment landscape for NSCLC but has proven incredibly important for personalizing patient care, transforming from a generic chemotherapy approach to a highly personalized, genomically driven treatment strategy. For advanced disease, chemotherapy was the standard.

Chemotherapy 73

Chemotherapy Compounding Pharmacies Hospitals Immunization 73

European Pharmaceutical Review

JANUARY 10, 2025

The National Institute for Health and Care Excellence (NICE) has recommended Lynparza (olaparib) for adults with HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations after chemotherapy. months with just standard chemotherapy. months, compared to 4.2

Chemotherapy 52

Chemotherapy 52

Pharmaceutical Technology

JULY 4, 2025

Go deeper with GlobalData Reports LOA and PTSR Model - Denosumab Biosimilar in Bone Metastasis Reports LOA and PTSR Model - Denosumab Biosimilar in Chemotherapy Effects Data Insights The gold standard of business intelligence. By inhibiting RANKL, denosumab hampers the bone degradation process, bolstering bone density and strength.

Chemotherapy 52

Chemotherapy Packaging Communication Hospitals 52

European Pharmaceutical Review

NOVEMBER 19, 2024

.” In a Q&A with EPR last year, Hoppin and Ratio’s Director, President and Chief Scientific Officer, Dr John Babich, described that “there is great hope of this class of drug specifically to work in conjunction with immunotherapeutics, given the lack of toxicity of radiopharmaceuticals in general compared to most chemotherapies.”

Chemotherapy 52

Chemotherapy FDA 52

Pharmacy Times

JUNE 25, 2025

1 Scientific evidence between January 1, 2016, and January 31, 2023, was included in the study. This was assessed by analyzing real-world pharmacoepidemiological data and conducting a systematic review and meta-analysis to further quantify this risk. Subscribe Now!

Compounding Pharmacies 73

Compounding Pharmacies Immunization Chemotherapy Compounding 73

Pharmacy Times

JUNE 6, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Compounding Pharmacies 65

Compounding Pharmacies Immunization Chemotherapy Compounding 65

Pharmacy Times

JUNE 18, 2025

PTCy recipients included those who received peripheral blood stem cells of haploidentical-related and mismatched unrelated donor transplants.

Compounding Pharmacies 73

Compounding Pharmacies Dosage Immunization Compounding 73

Pharmaceutical Technology

JULY 7, 2025

Akeega has been approved in Europe for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in combination with steroid hormone prednisolone since 2023. J&J is now attempting to widen the drug’s application to patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Labelling 52

Labelling Packaging Communication Hospitals 52

Pharmacy Times

JUNE 17, 2025

Martino, PharmD, BCOP, APh Kaitlyn Wells, PharmD Sam Martinez, PharmD, BCOP, BCPS Craig A. Stevens, PharmD, BCPS June 3rd 2025 S2. Martino, PharmD, BCOP, APh Kaitlyn Wells, PharmD Sam Martinez, PharmD, BCOP, BCPS Craig A. Stevens, PharmD, BCPS June 3rd 2025 S2.

Compounding Pharmacies 65

Compounding Pharmacies Hospitals Immunization Chemotherapy 65

Pharmacy Times

JUNE 23, 2025

Datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc) received FDA approval for treatment of adults with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy.

FDA 86

FDA Compounding Pharmacies Chemotherapy Immunization 86